Juniper investment company sells $2.73m of Orthofix Medical shares

Juniper Investment Company, LLC, a 10% shareholder and Orthofix Medical Inc.'s director, recently disposed of $2.73 million worth of Orthofix shares. These sales occurred on September 18 and September 21, 2026. On September 18, the company sold 120,000 shares at an average price of $8.7393 per share, ranging from $8.65 to $8.81.

The next day, an additional 190,000 shares were sold at a weighted average price of $8.8599 per share, with prices between $8.63 and $8.98. Together, the company sold 310,000 shares. The stock's value has since risen to $9.44, marking an 8.4% increase over the past week, though it has dropped 38% year-to-date. The shares were indirectly owned by the Juniper Targeted Opportunity Fund, L.P., managed by Juniper Investment Company, LLC, along with other funds.

Juniper Investment Company's managing members, John A. Bartholdson and Alexis P. Michas, disclaimed beneficial ownership, except for their financial interest. Following the transactions, Juniper Investment Company now indirectly owns 4,792,043 shares of Orthofix Medical. InvestingPro analysis suggests the stock is currently undervalued, with analysts forecasting profitability this year following recent losses.

Orthofix Medical reported second-quarter 2026 financial results, beating expectations with an adjusted loss per share of $0.39 and revenue of $210.93 million. The company also raised its full-year sales and adjusted EBITDA guidance, citing improved sales trends and restored Medicare benefits. However, challenges remain, particularly with U.S. spine distributors, and biologics performance remains flat compared to last year.

Stifel maintains a Buy rating on Orthofix Medical, with a price target of $13, highlighting the company's profitable growth at an attractive valuation.